Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    Aug 24, 2023
  • participants needed
    35
  • sponsor
    Northwestern University
Updated on 24 January 2021
cancer
hysterectomy
lymphoma
measurable disease
fungal infection
histone deacetylase inhibitor
lenalidomide
neutrophil count
revlimid
enteropathy
panniculitis
t-cell lymphoma
peripheral t-cell lymphoma
angioimmunoblastic t-cell lymphoma
mycosis fungoides
anaplastic large cell lymphoma
large cell lymphoma
hepatosplenic t-cell lymphoma
romidepsin
biopsy tissue
intestinal t-cell lymphoma
extranodal nk/t-cell lymphoma
hdac inhibitor

Summary

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).

Description

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of the combination of romidepsin plus lenalidomide in patients with previously untreated peripheral T-cell lymphoma (PTCL).

SECONDARY OBJECTIVES:

I. Evaluate the safety of the combination of romidepsin and lenalidomide. II. Further evaluate efficacy of the combination of romidepsin and lenalidomide.

III. Evaluate the delay to cytotoxic chemotherapy.

TERTIARY OBJECTIVES:

I. Evaluate the use of Northwestern Medicine (NM) positron emission tomography (PET)/computed tomography (CT) vs CT imaging in PTCL.

II. Validate a new prognostic model for newly diagnosed PTCL. III. Investigate the tumor immunohistochemical profile to identify potential biomarkers associated with prognosis and treatment response.

OUTLINE

Patients receive romidepsin intravenously (IV) over 4 hours on days 1, 8, and 15 and lenalidomide orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression, inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw from study treatment (or study as a whole), or general or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the treating investigator.

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 3 years.

Details
Condition Peripheral T-Cell Lymphoma, anaplastic large cell lymphoma, T-Cell Lymphoma, Angioimmunoblastic Lymphadenopathy, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Treatment laboratory biomarker analysis, Lenalidomide, romidepsin
Clinical Study IdentifierNCT02232516
SponsorNorthwestern University
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma or Stage IIIB Mycosis Fungoides/Sezary Syndrome or T-Cell Lymphoma or Stage IA Mycosis Fungoides/Sezary...?
Do you have any of these conditions: Stage III Cutaneous T-cell Non-Hodgkin Lymphoma or Peripheral T-Cell Lymphoma or Hepatosplenic T-cell Lymphoma or Adult Nasal Type Extranodal NK/T-cel...?
Histologically confirmed diagnosis of PTCL (using the most recent edition of the World Health Organization [WHO] Classification of Tumors of Hematopoietic and Lymphoid Tissues as guidance) including
Anaplastic large cell lymphoma, anaplastic large cell kinase (ALK)-negative
Angioimmunoblastic T-cell lymphoma
Enteropathy-type T-cell lymphoma
Extranodal natural killer (NK)/T-cell lymphoma, nasal type
Hepatosplenic gamma-delta T-cell lymphoma
Peripheral T-cell lymphoma, unspecified (not otherwise specified [NOS])
Transformed mycosis fungoides
Subcutaneous panniculitis-like T-cell lymphoma
NOTE: A copy of the pathology report is sufficient to register the patient to the trial; diagnosis of PTCL should have been based on identification in biopsy specimens of a peripheral T-cell lymphoma disorder characterized by positivity in the malignant cell population of at least 3 of the following T-cell markers: betaF1, cluster of differentiation (CD)2, CD3, CD4, CD5, CD7, CD8, and negativity of at least 2 of the following B-cell markers CD19, CD20, CD79alpha and paired box 5 (Pax-5); further, CD56 should be used for the diagnosis of the nasal type, while CD30, ALK-1 and Pax-5 (that should be negative) are required for the anaplastic type; CD10, chemokine (C-X-C motif) ligand 13 (CXCL13), programmed cell death (PD)-1 and CD21 are warranted for the diagnosis of angioimmunoblastic T-cell lymphoma along with Epstein-Barr virus-encoded small ribonucleic acid (RNA) (EBER) in situ hybridization; determination of mindbomb E3 ubiquitin protein ligase 1(Mib-1)/marker of proliferation Ki-67 (Ki-67) to be performed; finally, additional markers useful within the context of anaplastic large cell lymphoma, extranodal NK/T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma are TIA1 cytotoxic granule-associated RNA binding protein (TIA-1), granzyme B and perforin; it is acknowledged that no marker has absolute lineage specificity, and that immunophenotypic studies should be performed with panels of monoclonal antibodies; final diagnoses containing caveats such as "suspicious of" or "presumably" are considered inadequate for a patient to be enrolled in the trial
NOTE: Patients with adequate archived (well-preserved, formalin-fixed) biopsy tissue remaining will be required to submit a portion for exploratory studies; this is not optional if tissue is available; however, lack of adequate tissue for exploratory studies will not preclude patients from participating
Patients must have bi-dimensionally measurable disease (>= 1 cm) by CT imaging
NOTE: Patients with marrow-only disease are eligible; response for these patients will be assessed by repeat bone marrow biopsy
Patients must fit into one of the following categories
Age >= 18 years to < 60 years with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator
>= 60 years
Patients must have adequate organ and marrow function (documented within 14 days prior to registration) as outlined below
Absolute neutrophil count (ANC) >= 750/mcl
Hemoglobin >= 8 g/dl
Platelets >= 50,000/mcl
Total bilirubin =< 2 x upper limit normal (ULN)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum pyruvate glutamate transaminase [SPGT]) =< 3 x ULN
Creatinine =< 2 x ULN
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2
All patients must agree to use effective contraception while on study, and all patients must agree to undergo counseling sessions every 28 days about pregnancy precautions and risks of fetal exposure
Females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for at least 28 days following discontinuation of lenalidomide therapy
Males receiving lenalidomide must agree to use a latex condom during any sexual contact with FCBPs even if they have undergone a successful vasectomy
NOTE: A FCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following
criteria
Has not undergone a hysterectomy or bilateral oophorectomy
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
FCBP should be referred to a qualified provider of contraceptive methods, if needed
FCPB must have a negative urine or serum pregnancy test within 7 days prior to registration, and be willing to adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Patients must be free of any prior malignancies for >= 1 year
NOTE: The exception to this would be currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage 0) with histologically confirmed free margins of excision
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration

Exclusion Criteria

Patients with a diagnosis of any of the following are not eligible
Anaplastic large cell lymphoma, ALK-positive
Adult T-cell lymphoma/leukemia (ATLL)
Anaplastic large-cell lymphoma, primary cutaneous type
Precursor T-lymphoblastic lymphoma/leukemia
Mycosis fungoides/Sezary syndrome (except transformed Mycosis fungoides [MF])
NK-cell leukemia
T-cell granular lymphocytic leukemia
T-cell prolymphocytic leukemia
Patients must not have received prior systemic therapy for PTCL (except for corticosteroids for 10 or fewer days at any dose, no washout period required as long as they discontinue prior to starting study therapy); NOTE: topical treatment may have been given for prior existence of cutaneous lymphoma that has since become systemic PTCL; however, these topical therapies should be stopped at time of registration
Patients who received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within 4 weeks prior to registration are not eligible
Patients who received prior exposure to any other histone deacetylase (HDAC) inhibitors or immunomodulatory (IMID) agents for any reason are not eligible
Patients receiving ongoing treatment with any other investigational agents are not eligible
Patients who have known central nervous system (CNS) involvement of lymphoma are not eligible
Patients who have an uncontrolled intercurrent illness including, but not limited to, any of the following are not eligible
Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Psychiatric illness/social situations that would limit compliance with study requirements
Patients with a known human immunodeficiency (HIV) infection are not eligible
Patients who are pregnant or actively nursing an infant are not eligible
Patients with a QT interval > 500 msec (using the Bazett's formula) within 28 days prior to registration are not eligible
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note